Synapcell is a Contract Research Organization (CRO) focused on preclinical efficacy testing. Since our establishment in 2005, we support the biotech and pharma industry in the CNS drug development journey by providing our customers with robust go-no go in vivo assays as soon as the preclinical stage, with IND-ready data and report. That said, we are used to work with structures of any typology of size, from the small start-ups to the large pharmaceutical companies. Our partners are located internationally, across the US-LATAM, EMEA and APAC areas.

Through our cutting-edge platform based on electroencephalography, we developed our own translational in-vivo rodent models associated with robust EEG biomarkers, the MTLE mouse model of mesio temporal lobe epilepsy (MTLE) and the GAERS model of absence generalized seizures being our first models of expertise for more than 17 years. Besides our CRO expertise and primary focus on epilepsy, our R&D team is working on developping state-of-the-art EEG biomarkers as well as analysis methods, to keep up with the need of our Sponsors.

Our solution Cue® is based on the electroencephalography (EEG) technology, allowing us to record the electrical activity from the brain of rodents, mice and rats exclusively. Since EEG is routinely used by clinicians who recognize the method as one of the most translational tool to date, it makes our technology unique as it enables the discovery of specific EEG patterns used as surrogate biomarkers for neurologic disorders.
All in all, what makes us distinctive, besides our experience and expertise, is the unique approach to provide valuable data on specific indications, in settings that match as close as possible the clinical trials, very early in the life of a compound.

–  Therapeutic areas: Epileptic disorders, Movement disorders, Psychiatric disorders, Rare disorders

–  Based in: Saint-Ismier (FRANCE)

–  Employees: 11 – 50

– Created in: 2005